Previous studies have shown that several circulating markers of inflammation, such as interleukin‐6 (IL‐6), tumor necrosis factor‐α (TNF‐α), and C‐reactive protein (CRP), were observably higher in patients with glioblastoma compared to healthy controls.9 Accumulating evidence has also shown that these markers may be involved in the risk and survival of glioma. This evidence concerns the gene IL6 and glioma.